165 related articles for article (PubMed ID: 22479339)
1. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: a systematic review and meta-analysis.
Tan Y; Ding K; Su J; Trinh X; Peng Z; Gong Y; Chen L; Cui Q; Lei N; Chen X; Yu R
PLoS One; 2012; 7(3):e32789. PubMed ID: 22479339
[TBL] [Abstract][Full Text] [Related]
2. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.
Tan YW; Ye Y; Ge GH; Zhao W; Gan JH; Zhao Y; Niu ZL; Zhang DJ; Chen L; Yu XJ; Yang LJ
World J Gastroenterol; 2015 Feb; 21(7):2089-95. PubMed ID: 25717242
[TBL] [Abstract][Full Text] [Related]
3. Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment.
Wu F; Wu MJ; Zhuge XL; Zhu SM; Zhu B
Hepatobiliary Pancreat Dis Int; 2012 Apr; 11(2):172-6. PubMed ID: 22484586
[TBL] [Abstract][Full Text] [Related]
4. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
Akarsu M; Sengonul A; Tankurt E; Sayiner AA; Topalak O; Akpinar H; Abacioglu YH
J Gastroenterol Hepatol; 2006 Dec; 21(12):1783-8. PubMed ID: 17074014
[TBL] [Abstract][Full Text] [Related]
5. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
Arslan U; Ural O; Findik D
Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
[TBL] [Abstract][Full Text] [Related]
6. YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study.
Tan YW; Ge GH; Zhao W; Gan JH; Zhao Y; Niu ZL; Zhang DJ; Chen L; Yu XJ; Yang LJ
Braz J Infect Dis; 2012; 16(3):250-5. PubMed ID: 22729192
[TBL] [Abstract][Full Text] [Related]
7. The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation.
Pas SD; de Man RA; Fries E; Osterhaus AD; Niesters HG
J Clin Virol; 2002 Jul; 25(1):63-71. PubMed ID: 12126723
[TBL] [Abstract][Full Text] [Related]
8. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy.
Zhang X; Liu C; Gong Q; Zhang S; Zhang D; Lu Z; Wang Y
J Gastroenterol Hepatol; 2003 Dec; 18(12):1353-7. PubMed ID: 14675262
[TBL] [Abstract][Full Text] [Related]
9. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
10. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
11. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.
Perrillo R; Hann HW; Mutimer D; Willems B; Leung N; Lee WM; Moorat A; Gardner S; Woessner M; Bourne E; Brosgart CL; Schiff E
Gastroenterology; 2004 Jan; 126(1):81-90. PubMed ID: 14699490
[TBL] [Abstract][Full Text] [Related]
12. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
Liaw YF
J Gastroenterol Hepatol; 2002 Dec; 17 Suppl 3():S333-7. PubMed ID: 12472959
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy changes of short-term lamivudine therapy for chronic hepatitis B with emergence of YMDD mutation].
Deng H; Lv Y; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):368-9. PubMed ID: 15225437
[TBL] [Abstract][Full Text] [Related]
14. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y
Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
[TBL] [Abstract][Full Text] [Related]
15. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment.
Yuen MF; Sablon E; Libbrecht E; Van De Velde H; Wong DK; Fung J; Wong BC; Lai CL
Antivir Ther; 2006; 11(6):779-86. PubMed ID: 17310822
[TBL] [Abstract][Full Text] [Related]
16. Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection.
Ramezani A; Velayati AA; Roshan MR; Gachkar L; Banifazl M; Keyvani H; Aghakhani A
Int J Infect Dis; 2008 May; 12(3):252-5. PubMed ID: 17954033
[TBL] [Abstract][Full Text] [Related]
17. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients.
Seta T; Yokosuka O; Imazeki F; Tagawa M; Saisho H
J Med Virol; 2000 Jan; 60(1):8-16. PubMed ID: 10568756
[TBL] [Abstract][Full Text] [Related]
18. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines.
Huang ZM; Huang QW; Qin YQ; He YZ; Qin HJ; Zhou YN; Xu X; Huang MJ
World J Gastroenterol; 2005 Feb; 11(6):867-70. PubMed ID: 15682483
[TBL] [Abstract][Full Text] [Related]
19. Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population.
Alagozlu H; Ozdemir O; Koksal B; Yilmaz A; Coskun M
Asian Pac J Cancer Prev; 2013; 14(9):5489-94. PubMed ID: 24175847
[TBL] [Abstract][Full Text] [Related]
20. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Kazim SN; Chauhan R; Das BC; Sarin SK
J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
